Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder: A qualitative study
Open accessThe DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
BACKGROUND: One of the major challenges in treating major depressive disorder (MDD) is patients' non-adherence to medication. This study aimed to explore the barriers and facilitators of patients' adherence to antidepressants among outpatients with MDD. METHODS: Semi-structured and individual in-depth interviews were conducted among patients with MDD who were taking antidepressants, in the psychiatric clinic of a government-run hospital in Malaysia. Participants were purposively sampled from different genders and ethnicities. Interviews were conducted using a validated topic guide, and responses were audio-recorded, transcribed verbatim, checked, and analyzed using the grounded theory approach. RESULTS: A total of 30 patients were interviewed. Forty different themes and sub-themes were identified which were conceptually divided into two distinct categories related to barriers and facilitators to adherence. The barriers were: patient-specific, medication-specific, healthcare provision and system, social-cultural, and logistics. The facilitators were: having insight, perceived health benefits, regular activities, patient-provider relationship, reminders, and social support networks. CONCLUSIONS: Patient-specific barriers and medication side effects were the major challenges for adhering to treatment. Perceived health benefits and having insight on the need for treatment were the most frequently cited facilitators. Targeted interventions should be developed to address the key barriers, and promote measures to facilitate adherence in this group of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Qualitative Inquiry and Research Design: Choosing Among Five Approaches
Lewis, S. (2015) · Health Promotion Practice · doi:10.1177/1524839915580941 · Cited by 22,105
(2017) · Cited by 16,036
Back-translation for cross-cultural research.
Brislin, R. W. (1970) · Journal of Cross-Cultural Psychology · doi:10.1177/135910457000100301 · Cited by 14,091 · cited 1×
“All translations were done by a certified translator using Brislin’s backward forward translation [40].”
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386 · cited 1×
“MDD was rated as the fourth leading disabling condition [2], and according to projections for the year 2030, it will rise to be among the top three leading disabling conditions together with ischemic heart disease and HIV/AIDS [4].”
Diagnostic and Statistical Manual of Mental Disorders
Siegel, L. J., & Fletcher‐Janzem, E. (2008) · Encyclopedia of Special Education · doi:10.1002/9780470373699.speced0655 · Cited by 8,477
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,381
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Research works printed but not linked: 1
- H Leventhal, 1997, Illness representations: theoretical foundations, Perceptions of health and illness, 2, 19
Cited by
Kvarnström, K., Westerholm, A., Airaksinen, M., & Liira, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071100 · Cited by 470
“Poor access to healthcare and long waiting times cause poor medication adherence [55].”
BackgroundMethodInfluentialOliva, V., Lippi, M., Paci, R., Del Fabro, L., Delvecchio, G., Brambilla, P., De Ronchi, D., Fanelli, G., & Serretti, A. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110266 · Cited by 219
Sales, A. J., Fogaça, M. V., Sartim, A. G., Pereira, V. S., Wegener, G., Guimarães, F. S., & Joca, S. R. L. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1143-4 · Cited by 198
Deng, M., Zhai, S., Ouyang, X., Liu, Z., & Ross, B. (2022) · BMC Psychiatry · doi:10.1186/s12888-021-03681-6 · Cited by 75
“Attitudes towards mental disorders/treatment Multiple studies have shown that psychiatric patients’ or their family members’ attitudes towards mental disorders and treatment can impact medication adherence to various degrees [16, 26, 37, 38].”
BackgroundLee, M. T., Peng, W.-H., Kan, H.-W., Wu, C.-C., Wang, D.-W., & Ho, Y.-C. (2022) · Biomedicines · doi:10.3390/biomedicines10051005 · Cited by 65
“The severe adverse effects associated with the pharmacotherapy, including cardiac toxicity, hyperpiesia, sexual dysfunction, body weight gain, and sleep disorders, often hamper patients’ adherence [5,6].”
BackgroundNiarchou, E., Roberts, L., & Naughton, B. D. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231224171 · Cited by 89
“It is well established that low levels of MA are linked with poor clinical outcomes and higher relapse in depressive disorder (Ho et al., 2017); therefore, this finding should not be overlooked.”
BackgroundResultInfluentialFactors Associated with Antidepressant Medication Non-adherence
Marasine, N. R., & Sankhi, S. (2020) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2020.49799 · Cited by 82
Munawar, K., Mukhtar, F., Choudhry, F. R., & Ng, A. L. O. (2021) · Asia-Pacific Psychiatry · doi:10.1111/appy.12475 · Cited by 53
“Possible reasons for this lack may also be adherence to traditional cultural beliefs about the aetiology of mental health issues and traditional practices (Ho et al., 2017).”
BackgroundDell’Osso, B., Albert, U., Carrà, G., Pompili, M., Nanni, M. G., Pasquini, M., Poloni, N., Raballo, A., Sambataro, F., Serafini, G., et al. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00306-2 · Cited by 52
Mental Health Apps in Psychiatric Treatment: A Patient Perspective on Real World Technology Usage
Chiauzzi, E., & Newell, A. (2019) · JMIR Mental Health · doi:10.2196/12292 · Cited by 46
“For many patients, making day-to-day choices about medications reflect their own real-world priorities rather than those of their doctors [60].”
Bunka, M., Wong, G. W. K., Kim, D., Edwards, L., Austin, J., Doyle‐Waters, M. M., Gaedigk, A., & Bryan, S. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115102 · Cited by 50
Husain, M. I., Blumberger, D. M., Castle, D. J., Ledwos, N., Fellows, E., Jones, B. D. M., Ortiz, A., Kloiber, S. M., Wang, W., Rosenblat, J. D., et al. (2023) · BJPsych Open · doi:10.1192/bjo.2023.535 · Cited by 57
Stigmatizing Beliefs About Depression in Diverse Ethnic Groups of Asian Americans
Jung, H., Cho, Y. J., Rhee, M., & Jang, Y. (2019) · Community Mental Health Journal · doi:10.1007/s10597-019-00481-x · Cited by 46
Srimongkon, P., Aslani, P., & Chen, T. F. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s160728 · Cited by 39
“42 Although positive effects of antidepressant therapy was one of the most powerful facilitators, paradoxically it also led to discontinuation, in some cases, as individuals felt they no longer needed treatment, as they were “better”.”
Pharmacogenomic Clinical Decision Support: A Scoping Review
Smith, D. M., Wake, D. T., & Dunnenberger, H. M. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2711 · Cited by 45
de León, B. G., Sacks, A. A., Acosta, F. J., del Pino‐Sedeño, T., Ramos‐García, V., Álvarez, C. R., Bejarano‐Quisoboni, D., & Trujillo‐Martín, M. M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192416788 · Cited by 44
“To the best of the authors’ knowledge, few qualitative studies with this aim have been conducted to date [20,21].”
BackgroundGenetics of Treatment Outcomes in Major Depressive Disorder: Present and Future
Fabbri, C., & Serretti, A. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.1.1 · Cited by 44
“Another common issue is represented by side effects, which are frequently associated with poor treatment adherence and early treatment discontinuation [5].”
BackgroundMarasine, N. R., Sankhi, S., Lamichhane, R., Marasini, N. R., & Dangi, N. B. (2020) · Depression Research and Treatment · doi:10.1155/2020/7024275 · Cited by 44
“A study from Malaysia reported that SSRIs were the most frequently prescribed antidepressants whose prescriptions increased rapidly in the last decade [16].”
BackgroundInfluentialChevance, A., Tomlinson, A., Ravaud, P., Touboul, S., Henshall, C. L., Tran, V.-T., & Cipriani, A. (2022) · Evidence-Based Mental Health · doi:10.1136/ebmental-2021-300418 · Cited by 31
Tangiisuran, B., Rajendran, V., Sha’aban, A., Daud, N. A. A., & Nawi, S. N. M. (2021) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-021-01336-w · Cited by 33
Self-citationExperience of antidepressant use and discontinuation: A qualitative synthesis of the evidence
Crowe, M., Inder, M., & McCall, C. (2022) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12850 · Cited by 32
“The theme was developed from the findings in14 studies (Anderson et al., 2015; Cartwright et al., 2018; Fullager, 2009; Garfield et al., 2003; Ho et al., 2017; Huijbers et al., 2020; Jaffray et al., 2014; Knudsen et al., 2002; Lafrance & Stoppard, 2006; McMullen & Herman, 2009; Ridge et al., 2015;…”
BackgroundTransdermal Route: A Viable Option for Systemic Delivery of Antidepressants
Tijani, A. O., Nunez, E., Singh, K., Khanna, G., & Puri, A. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.05.015 · Cited by 29
Wang, H., Liao, Y., Guo, L., Zhang, H., Zhang, Y., Lai, W., Teopiz, K. M., Song, W., Zhu, D., Li, L., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04297-0 · Cited by 26
Chai, X., Liu, Y., Mao, Z., & Li, S. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03144-y · Cited by 34
“Structured, closed-end surveys do not allow patients to fully express themselves and to respond beyond the survey options [19].”
BackgroundMedication Adherence in Cancer Patients: A Comprehensive Review
Reshma, V., Chacko, A. M., Abdulla, N. H., Annamalai, M., & Kandi, V. (2024) · Cureus · doi:10.7759/cureus.52721 · Cited by 69
“Low toxicity, mild side effects, and the oral delivery of the drug appear to encourage medication compliance [44].”
BackgroundKhalifeh, A. H., & Hamdan‐Mansour, A. M. (2020) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20201015-05 · Cited by 31
Husain, M. I., Chaudhry, I. B., Khoso, A. B., Kiran, T., Khan, N., Ahmad, F., Hodsoll, J. P., Husain, M. O., Naqvi, H., Nizami, A. T., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.0147 · Cited by 28
So, Antidepressant Drugs have Serious Adverse Effects, but what are the Alternatives?
Ali, A. M. (2018) · Novel Approaches in Drug Designing & Development · doi:10.19080/napdd.2018.04.555636 · Cited by 22
“It is reported that more than half of those who use antidepressants discontinue treatment because of lack of efficacy and adverse effects such as weight gain and sexual dysfunction [107,108].”
BackgroundExtended Producer Responsibility for Pharmaceuticals
Alev, I., Atasu, A., Toktay, L. B., & Zhang, C. (2015) · Manufacturing & Service Operations Management · doi:10.1287/msom.2020.0962 · Cited by 22
Unni, E., Gupta, S., & Sternbach, N. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.010 · Cited by 27
Jacobsen, P. L., Thorley, E. M., & Curran, C. (2020) · Neurology, Psychiatry and Brain Research · doi:10.1016/j.npbr.2020.03.002 · Cited by 19
Vasiliu, O. (2023) · Pharmaceuticals · doi:10.3390/ph16030411 · Cited by 22
“Medication-specific aspects that have been correlated with treatment adherence were adverse effects, delayed onset of action, and subtherapeutic doses, but also complicated dosing schedules or titration strategies [97,98].”
BackgroundDing, A., Dixon, S. W., Ferries, E. A., & Shrank, W. H. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.3.379 · Cited by 24
Ta, J. T., Sullivan, S. D., Tung, A., Oliveri, D., Gillard, P. J., & Devine, B. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.2.223 · Cited by 24
Taipale, H. T., Niederkrotenthaler, T., Helgesson, M., Sijbrandij, M., Berg, L., Tanskanen, A. J., & Mittendorfer‐Rutz, E. (2020) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-020-01951-4 · Cited by 17
Zhou, Q., Wu, Z., Wang, Y., Liu, X., Chen, J., Wang, Y., Su, Y., Zhang, C., Peng, D., Hong, W., et al. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13030 · Cited by 20
Sankhi, S., Marasine, N. R., Sankhi, S., & Lamichhane, R. (2020) · BioMed Research International · doi:10.1155/2020/6682928 · Cited by 13
“ADRs are the significant determinants of adherence associated with antidepressant medications and are reported to be high among patients with depression [9].”
BackgroundGastrointestinal adverse events associated with SNRIs: A FAERS-based pharmacovigilance study
Lin, J., Wei, S., Peng, Y., Liang, C., Jiao, W., Ji, Y., Deng, Y., Yan, F., & Xi, J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119484 · Cited by 12
Alemayehu, Y., Asfaw, H., & Girma, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271713 · Cited by 13
“This association is consistent with studies done in Malaysia [18], Czech Republic [21] and USA [19] The possible reason for the association might be those who were non adherent to the treatment have poor ability to control or recover from the illness, worsening their level of self-stigma [39].”
Mathew, S. J., Cutler, A. J., Visitacion, N. C., Gold, M., Yuan, J. X. ‐., & Aurora, B. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001967 · Cited by 15
Brydges, S., Rennick‐Egglestone, S., & Anderson, C. (2019) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2019.10.016 · Cited by 14
Sriramalu, S. B., Elangovan, A. R., Isaac, M., & Raman, K. J. (2021) · International Journal of Social Psychiatry · doi:10.1177/00207640211008462 · Cited by 16
“The community-based approach as suggested by Chandrashekar et al. (1981), Olfson et al. (2006) and Ho et al. (2017) such as doorstep delivery of services home visit approaches, social support, patient-provider relationship, reminders and social support networks would be of great help in addressing…”
BackgroundAssociation between health‐related quality of life and nonadherence to antihypertensive medication
Kim, K. Y. (2023) · Nursing Open · doi:10.1002/nop2.1599 · Cited by 16
“Nonadherence to medication is a major issue in the treatment of major depressive disorders (Ho et al., 2017).”
BackgroundMuhammad, N., Ullah, S. R., Nagi, T. K., & Yousaf, R. A. (2023) · Cureus · doi:10.7759/cureus.37828 · Cited by 16
“According to studies, older patients perceive a much greater need for anti-depressant medication than younger ones [33].”
BackgroundOnwusah, D. O., Ojewole, E. B., Manyangadze, T., & Chimbari, M. J. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s416843 · Cited by 15
“We conducted face-to-face, in-depth interviews using a semi-structured interview schedule with predetermined open-ended questions developed based on previously published qualitative research, 40 and the study’s objectives (Supplementary File 1).”
MethodDomingos, L. B., Müller, H. K., da Silva, N. R., Filiou, M. D., Nielsen, A. L., Guimarães, F. S., Wegener, G., & Joca, S. R. L. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109870 · Cited by 11
Meng, Y., Chiu, C., Kapoor, M., Li, S., Kaur, N., Marr, P., Kwan, D., Leblanc, K., Ji, C., & Papoushek, C. (2024) · Journal of Primary Care & Community Health · doi:10.1177/21501319241286313 · Cited by 18
“15 Some erroneous beliefs included taking antide-pressants only when depressive symptoms are present and that antidepressants cause kidney damage with long-term use.”
BackgroundInfluentialNodari, C. H., Quadros, N. D. D., Chiarentin, R., da Silva, F. P., Morisso, F. D. P., Charão, M. F., Fleck, J. D., de Mattos, C. B., Betti, A. H., & Verza, S. G. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00412-w · Cited by 10
“Antidepressant medicines have been demonstrated to be effective in treating MDD to reduce the symptoms [2], but severe cognitive impairment may lead to unsatisfactory response and remission rates with the use of traditional selective serotonin reuptake inhibitors [4].”
BackgroundKhalifeh, A. H., Alhalaiqa, F., Hamaideh, S. H., Horne, R., & Hamdan‐Mansour, A. M. (2023) · International Journal of Mental Health Nursing · doi:10.1111/inm.13113 · Cited by 18
Study of Adverse Drug Reaction of Anti-Depressants in Adult Patients: A Nepalese Perspective
Shahi, U. B., Acharya, A., Timalsina, S., Gautam, A., Swain, K. C., & Panthi, S. (2023) · Psychiatry International · doi:10.3390/psychiatryint4030022 · Cited by 11
Chan, M. M. Y., & Han, Y. M. Y. (2020) · Neural Plasticity · doi:10.1155/2020/8854412 · Cited by 12
“However, these medications are often associated with undesirable side effects, such as extrapyramidal side effects induced by not only first- but also second-generation antipsychotics [22], as well as hyponatremia, bleeding, or seizures induced by serotonin reuptake inhibitors (SSRIs) [23], which hinder treatment comp…”
BackgroundNonpharmacological Treatment for Supporting Social Participation of Adults with Depression
Phadsri, S., Shioji, R., Tanimura, A., Jaknissai, J., Apichai, S., & Sookruay, T. (2021) · Occupational Therapy International · doi:10.1155/2021/8850364 · Cited by 15
“The negative perception of pharmacological treatment [4] among this group is mainly due to the unpleasant side effects they experienced, such as drowsiness, weight gain, fatigue, constipation, and sexual dysfunction [10, 11], which often led to inadequate work capacity and loss of social functioning [6].”
BackgroundZavorotnyy, M., Ehrlich, F., & Nenadić, I. (2020) · PsyCh Journal · doi:10.1002/pchj.355 · Cited by 11
Persistence of antidepressant use among refugee youth with common mental disorder
Taipale, H. T., Niederkrotenthaler, T., Tanskanen, A. J., Cullen, A. E., Helgesson, M., Berg, L., Sijbrandij, M., Klimek, P., & Mittendorfer‐Rutz, E. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.07.096 · Cited by 11
Talbot, A., Lee, C., Ryan, S., Roberts, N., Mahtani, K. R., & Albury, C. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01819-3 · Cited by 18
“One study was conducted in Austria [58], one in Canada [61], one in Denmark [55], one in Malaysia [56], five in the UK [14, 53, 54, 59, 60], and two in the USA [52, 57].”
BackgroundResultInfluentialFactors associated with loss to follow-up of outpatients with depression in general hospitals
Zhang, J., & Ye, C. (2020) · Journal of International Medical Research · doi:10.1177/0300060520925595 · Cited by 9
“Many studies outside China have focused on antidepressant adherence.(4,9,10) Sexual side effects, low self-efficacy, female sex, and low education level are the primary reasons for low treatment adherence.”
BackgroundXie, P., Li, H.-Q., Peng, W.-L., & Yang, H. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s444800 · Cited by 8
“48 This provides limited reference for future intervention research and the development of medication management strategies.”
BackgroundWang, G., Si, T., Imperato, J. S., Yang, L., Zou, K. H., Jin, Y., Pappadopulos, E. A., Yan, L., Li, J. Z., & Yu, W. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14522 · Cited by 9
Accinni, T., Panfili, M., Tarsitani, L., Biondi, M., Pasquini, M., & Maraone, A. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/3801235 · Cited by 10
“To date, clinicians must address remaining unresolved needs in relation to MDD treatments, considering that too often insufcient efectiveness and a difcult tolerability profle of antidepressant drugs may lead to poor adherence to treatments [5].”
Rahman, S. G., Filatova, S., Chen, L., Björkenstam, E., Taipale, H. T., & Mittendorfer‐Rutz, E. (2021) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-021-02139-0 · Cited by 8
Santina, T., Lauzier, S., Gagnon, H., Villeneuve, D., Moisan, J., Grégoire, J., & Guillaumie, L. (2018) · Pharmacy · doi:10.3390/pharmacy6020039 · Cited by 13
“Adverse effects [13,14], lack of support from the prescribing physician [14,15], lack of confidence in the efficacy of ADs [16], holding a negative opinion of ADs [12,13,17,18], and being strongly affected by the social stigma associated with the diagnosis of a mental health problem [16,19] appeared to negatively infl…”
BackgroundHalim, R., Kaur, M., Mokhtar, S. S. S., Chemi, N. B., Sajatovic, M., Tan, Y. K., Siau, C. S., & Ng, C. G. (2025) · Psychology Research and Behavior Management · doi:10.2147/prbm.s485333 · Cited by 7
Issac, A., Nayak, S. G., George, R., Priyadarshini, T., & Jacob, J. (2025) · Nursing and Health Sciences · doi:10.1111/nhs.70153 · Cited by 13
Jia, H., Yiyun, C., Zhiguo, W., Su, Y., Zhang, M., Yifan, S., Zhu, N., Feng, J., Fang, Y., & Daihui, P. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.116 · Cited by 7
Potential strategies to optimize the efficacy of antidepressants: Beyond the monoamine theory
Gammoh, O., & Bashatwah, R. M. (2023) · Electronic Journal of General Medicine · doi:10.29333/ejgm/13295 · Cited by 7
“Factors associated with nonadherence include poor patient education and counseling by health care providers, the patient’s misperception of depression, the polypharmacy in case of geriatrics, stigma and other social barriers [9-13].”
BackgroundBarriers to Treatment Adherence Among Older Adults With Type 2 Diabetes: A Qualitative Study
Maghsoudi, Z., Sadeghi, A., Oshvandi, K., Ebadi, A., & Tapak, L. (2023) · Journal of Gerontological Nursing · doi:10.3928/00989134-20221206-04 · Cited by 9
Sartori, D. P., de Oliveira, N. F., Valentim, J. T., Silva, D. M. A., Mallmann, A. S. V., Oliveira, I. C. M., Chaves, R., Capibaribe, V. C. C., de Carvalho, A. M. R., Rebouças, M. D. O., et al. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112487 · Cited by 10
Chen, C., Lun, Y., Yu, J., Zhao, X., Su, S., Zhao, M., Yan, Y., Wang, J., Fu, R., An, F., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1501381 · Cited by 6
Boskovic, D. H., Liang, S., Parab, P., Wiggins, E., & Liberman, J. N. (2023) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s402357 · Cited by 5
“For patients with MDD, studies have reported a range of medication nonadherence of 10%–60%.(8) Poor medication adherence has both clinical and economic consequences in patients with SMI.”
Backgrounddu Plessis, J. M., Poggenpoel, M., Myburgh, C. P. H., & Temane, A. M. (2021) · Curationis · doi:10.4102/curationis.v44i1.2105 · Cited by 6
Complex breathlessness: assessment of treatment adherence and treatable traits
McLoughlin, R. F., & McDonald, V. M. (2022) · European Respiratory Society eBooks · doi:10.1183/2312508x.10013721 · Cited by 5
Antidepressant adherence among outpatients with major depressive disorder
Yassen, A. O., Mahmud, N. M., Bilal, A. D., & Abd Wahab, M. S. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e123345 · Cited by 4
A risk identification model for detection of patients at risk of antidepressant discontinuation
Zolnour, A., Eldredge, C. E., Faiola, A. J., Yaghoobzadeh, Y., Khani, M., Foy, D., Topaz, M., Kharrazi, H. H. K., Fung, K. W., Fontelo, P. A., et al. (2023) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2023.1229609 · Cited by 5
“Using these risk factors, we created an initial analytical framework to analyze the patients’ reviews of antidepressants (van Servellen et al., 2011; Ho et al., 2017; Falcaro et al., 2019; Henssler et al., 2019).”
BackgroundMethodHijazi, B. M., Popovici, I., Nusair, M. B., & Alvarez, G. (2023) · Journal of Pharmaceutical Health Services Research · doi:10.1093/jphsr/rmad041 · Cited by 4
Zurchimitten, G., Camerini, L., Izídio, G. S., & Ghisleni, G. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111154 · Cited by 6
Stephenson, J. J., Touya, M., Chrones, L., Pandya, S. A., Teng, C., & Clayton, A. H. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100750 · Cited by 4
Wang, X., Juntasopeepun, P., Panuthai, S., & Suwankruhasn, N. (2025) · Nursing and Health Sciences · doi:10.1111/nhs.70192 · Cited by 3
“Additionally, non-adherence may be seen as irresponsible, leading to social stigma or criticism from family and peers (Ho et al. 2017).”
Raveendran, S., Singh, D., Burke, M. C., McAuliffe‐Fogarty, A. H., Parikh, S. V., McIntyre, R. S., Roy, A., Martin, M., Chrones, L., Opler, M. G. A., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04922-6 · Cited by 3
Hamlin, M., Holmén, J., Wentz, E., Aiff, H., Ali, L., & Steingrímsson, S. (2023) · JMIR Mental Health · doi:10.2196/48843 · Cited by 5
“Nonadherence increases the risk of deterioration of psychiatric symptoms, with an increased number of emergency visits and hospitalizations, resulting in not only great suffering at an individual level but also an increased economic burden on the health care system [4,5].”
BackgroundHong, J. S. W., Ostinelli, E. G., Kamvar, R., Smith, K., Walsh, A. E. L., Kabir, T., Tomlinson, A., & Cipriani, A. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05950-6 · Cited by 3
“On average, antidepressants reduce the severity of depressive symptoms [3], but adherence to these medications can be reduced by the occurrence of adverse events (AEs, defined as unwanted events or symptoms that may or may not be caused by the treat-ment) [4, 5].”
BackgroundComplementary and Alternative Therapies for Treatment-Resistant Depression: A Clinical Perspective
Yoon, R. S. Y., Ravindran, N., & Ravindran, A. V. (2018) · Springer eBooks · doi:10.1007/978-3-319-70311-4_12 · Cited by 5
dosReis, S., Peña, D. E., Fincannon, A., Gorman, E. F., & Amill‐Rosario, A. (2024) · Patient · doi:10.1007/s40271-024-00706-6 · Cited by 3
“Perceptions of dependence on drugs and misunderstanding about MDD and antidepressants are concerns that can lead to poor adherence [9].”
Kalaman, C. R., Ibrahim, N., Cham, C. Q., Ho, M. C., Visvalingam, U., Rahman, F. N. A., Shahabuddin, F. A., Halim, M. R. T. A., & Siau, C. S. (2024) · Cambridge Prisms Global Mental Health · doi:10.1017/gmh.2024.80 · Cited by 4
“Given the importance of medication adherence, a deeper understanding of the challenges experienced, particularly among adolescents with a psychiatric disorder in Malaysia, will help inform interventions relevant to our context (Dikec et al., 2022; Ho et al., 2017; Zarea et al., 2016).”
InfluentialMahoney, D. E., & Russell, C. L. (2021) · Journal of Reproduction & Infertility · doi:10.18502/jri.v22i3.6719 · Cited by 4
Factors Associated with Psychotropic Medications Literacy among Community Pharmacists
Alqudah, A. M., Al‐Taani, G. M., Handal, D., Sharab, R. A., Shreideh, R. A., Al‐Smadi, A. M., Qnais, E. Y., & Gammoh, O. (2023) · Medicina · doi:10.3390/medicina59030618 · Cited by 3
Munira, L., Liamputtong, P., Herman, B. Z., & Viwattanakulvanid, P. (2025) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-025-02819-1 · Cited by 6
“…studies showing that factors like low quality of life, illness duration, symptom severity, history of hospitalization, comorbid physical conditions, limited social support, self-stigma, and substance use are correlated with treatment non-adherence in patients with depressive disorders [37–41 ].”
Jayasree, A., Shanmuganathan, P., Ramamurthy, P., & Cumara, A. M. (2024) · Journal of Young Pharmacists · doi:10.5530/jyp.2024.16.41 · Cited by 2
Rajper, A. B., Dars, J. A., Iqbal, F., Rasool, G., Lal, C., Hyder, M., Afridi, M. I., Minhas, F. A., & Abbas, K. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22161441 · Cited by 1
A Review on Barriers of Medication Adherence in the Chronic Diseases
Kumaraswamy, M., Samraksha, M., N, M. M., & B, S. P. (2022) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2022.v75i02.003 · Cited by 2
“Non-adherence may be exacerbated by comorbidity.(38)”
Influência de Fatores Psicológicos e Sociais nos Comportamentos Preventivos de Saúde dos Homens
Falcão-Lima, G. O., Silva-Santos, L. C., & Faro, A. (2023) · Revista Psicologia e Saúde · doi:10.20435/pssa.v14i4.1862 · Cited by 2
Somanathan, R., Gandhi, S., Sivakumar, T., Manjunatha, N., Jayarajan, D., Thirthalli, J., & Parthasarathy, R. (2023) · Indian Journal of Psychological Medicine · doi:10.1177/02537176231207986 · Cited by 1
“23,24,35 Contrary to this, there was no report of a lack of rapport/ therapeutic alliance in the current study.”
BackgroundChiká, L. P., & Nunes, F. D. L. (2024) · OBSERVATÓRIO DE LA ECONOMÍA LATINOAMERICANA · doi:10.55905/oelv22n2-039 · Cited by 1
Sriramalu, S. B., Elangovan, A. R., Isaac, M., & Raman, K. J. (2024) · Indian Journal of Social Psychiatry · doi:10.4103/ijsp.ijsp_147_23 · Cited by 1
Family Psychoeducation for Major Depressive Disorder: A Systematic Review
Obieche, O., Tan, J. (., Sharma, S., Bressington, D. T., Wang, T., & Li, M. (2025) · International Journal of Mental Health Nursing · doi:10.1111/inm.70205 · Cited by 2
Adherence to antidepressant therapy: clinical experience on the example of agomelatine
Петрова, Н. Н. (2022) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2022-4-82-86 · Cited by 1
Reproductive toxicity of JJH201501 in rats: Perinatal study
Sun, M., Peng, Y., & Qiao, H. (2024) · Birth Defects Research · doi:10.1002/bdr2.2303 · Cited by 1
“Antidepressants have demonstrated efficacy in reducing MDD symptoms (Ho et al., 2017).”
BackgroundMikkola, H., Aarnio, E., Hämeen‐Anttila, K., Airaksinen, M., Dimitrow, M. S., & Saastamoinen, L. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-13402-4 · Cited by 1
Compliance and Psychoeducation
Unterecker, S. (2019) · Springer eBooks · doi:10.1007/978-3-319-56015-1_6-1 · Cited by 1
Khan, S. P., Naqvi, S., Rizwan, R., Ansari, M., Emad, S., Khan, H. U. R., Akhtar, A., Syed, M., Ehsan, N., & Moorad, A. (2021) · Annals of Psychophysiology · doi:10.29052/2412-3188.v8.i1.2021.24-33 · Cited by 1
Assessing Refill Data Among Different Classes of Antidepressants.
Stewart, H., & Basit, S. A. (2019) · PubMed
Metadata
- Authors
- Ho, S. C., Jacob, S. A., & Tangiisuran, B.
- Affiliations
- Universiti Sains Malaysia (MY)
- Monash University Malaysia (MY)
- Corresponding author
- Tangiisuran, Balamurugan
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-06-14
- Volume
- 12
- Issue
- 6
- Pages
- e0179290
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5470687
- OpenAlex
- W2626759055
- Semantic Scholar
- 15c830767f4fc2452e2bb2b9d1b2750ab26107d9
- Cited by
- 129
- References
- 83
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 29 · 2023: 23 · 2022: 19 · 2021: 15 · 2020: 15 · 2019: 5 · 2018: 7
- FWCI
- 7.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- Universiti Sains Malaysia (Short Term Grant)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- antidepressant adherence, major depressive disorder, medication non-adherence, barriers to adherence, facilitators of adherence, outpatients, patient-provider relationship, adverse drug reactions, social support, perceived health benefits, insight into illness, medication reminders
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Surveys and Questionnaires, Risk Factors, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.